Login Register Cart 0
Generic placeholder image

Current Chemical Biology

Editor-in-Chief

ISSN (Print): 2212-7968
ISSN (Online): 1872-3136

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Preparation and Characterization of PEGylated C18 Fatty Acids/Anti-SNAP25 Antibody-Targeted Liposomes

Author(s): Lai Ti Gew*, Vicit Rizal Eh Suk and Misni Misran

Volume 13, Issue 2, 2019

Page: [129 - 139] Pages: 11

DOI: 10.2174/2212796812666180912113156

Price: $65

Abstract

Background: Unsaturated C18 fatty acids, such as oleic acid (L1), linoleic acid (L2), and linolenic acid (L3), are a good choice of lipids to prepare liposomes. They are inexpensive, biocompatible, nontoxic, and readily available compared with phospholipids. Moreover, cis-double bonds of unsaturated fatty acids prevent the packing of molecules which increases membrane fluidity in liposomes making them a good choice of starting materials to prepare liposomes.

Objective: Unsaturated C18 fatty acid liposomes, as well as their PEGylated and non- PEGylated antibody-targeted liposomes, were prepared and characterized.

Methods: The particle size and zeta potential of the prepared liposomes (1 mM, pH = 7.4) for 28 and 14 days, respectively, were monitored and characterized. Membrane-bound antibodies Anti-SNAP25 (AS25) and DOPE PEG2000 (DP) were conjugated to pure C18 fatty acid liposomes to achieve stable fatty acid formulations.

Results: The mean particle sizes of pure L1, L2, and L3 liposome solutions were 125, 129, and 122 nm respectively, while their polydispersity index values were 0.28, 0.21, and 0.40 respectively. A large negative zeta potential value of 45 mV was observed due to anionic carboxylate head-group of pure liposomes. The incorporation of AS25 into L1/DP, L2/DP, and L3/DP liposome solutions stabilized their mean particle size and zeta potential measurements over 28 and 14 days, respectively.

Conclusion: L1/DP/AS25 was found to be the most stable PEGylated antibody-targeted liposome system because its particle size remained between 90 and 125 nm in 28 days. Transmission electron microscopy observations also supported the incorporation of AS25 and DP on the membrane surface as predicted.

Keywords: Stealth liposomes, drug delivery systems, therapeutic proteins, biotechnology, nanotechnology, Liposomes.

« Previous Next »
Graphical Abstract

[1]
Weiss A, Neuberg P, Philippot S, Erbacher P, Weill CO. Intracellular peptide delivery using amphiphilic lipid‐based formulations. Biotechnol Bioeng 2011; 108(10): 2477-87.
[2]
Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery–liposomes versus lipid nanoparticles. Int J Nanomedicine 2007; 2(4): 595.
[3]
Pisal DS, Kosloski MP, Balu‐Iyer SV. Delivery of therapeutic proteins. J Pharm Sci 2010; 99(6): 2557-75.
[4]
Rawat M, Singh D, Saraf S, Saraf S. Lipid carriers: A versatile delivery vehicle for proteins and peptides. Yakugaku zasshi-. J Pharm Soc Jap 2008; 128(2): 269-80.
[5]
Chang HI, Yeh MK. Clinical development of liposome-based drugs: Formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 2012; 7: 49.
[6]
Semple SC, Chonn A, Cullis PR. Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo. Adv Drug Deliv Rev 1998; 32(1-2): 3-17.
[7]
Mastrobattista E, Koning GA, Storm G. Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Deliv Rev 1999; 40(1-2): 103-27.
[8]
Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4(2): 145.
[9]
Debotton N, Parnes M, Kadouche J, Benita S. Overcoming the formulation obstacles towards targeted chemotherapy: In vitro and in vivo evaluation of cytotoxic drug loaded immunonanoparticles. J Control Release 2008; 127(3): 219-30.
[10]
Laginha K, Mumbengegwi D, Allen T. Liposomes targeted via two different antibodies: assay, B-cell binding and cytotoxicity. Biochim Biophys Acta 2005; 1711(1): 25-32.
[11]
Lundberg BB, Griffiths G, Hansen HJ. Cellular association and cytotoxicity of anti-CD74-targeted lipid drug-carriers in B lymphoma cells. J Control Release 2004; 94(1): 155-61.
[12]
Park J, Kirpotin D, Hong K, et al. Tumor targeting using anti-her2 immunoliposomes. J Control Release 2001; 74(1-3): 95-113.
[13]
Morigaki K, Walde P. Fatty acid vesicles. Curr Opin Colloid Interface Sci 2007; 12(2): 75-80.
[14]
Teo YY, Misran M, Low KH, Zain SM. Effect of Unsaturation on the stability of C18 polyunsaturated fatty acids vesicles suspension in aqueous solution. Bull Korean Chem Soc 2011; 32(1): 59-64.
[15]
Tan HW, Misran M. Characterization of fatty acid liposome coated with low-molecular-weight chitosan. J Liposome Res 2012; 22(4): 329-35.
[16]
Teo YY, Misran M, Low KH. Effect of pH on physicochemical properties and encapsulation efficiency of PEGylated linolenic acid vesicles. J Chem 2012; 9(2): 729-38.
[17]
Teo YY, Misran M, Low KH. Effect of PEGylated lipid and Lecinol S-10 on physico-chemical properties and encapsulation efficiency of palmitoleate–palmitoleic acid vesicles. J Liposome Res 2014; 24(3): 241-8.
[18]
Gew LT, Misran M. Energetic mixing of anti‐SNAP25 on lipid monolayers: Degree of saturation of C18 fatty acids. Surf Interface Anal 2017; 49(5): 388-97.
[19]
Gew LT, Misran M. Interaction between C18 fatty acids and DOPE PEG2000 in Langmuir monolayers: Effect of degree of unsaturation. J Biol Phys 2017; 43(3): 397-414.
[20]
Hodel A. Molecules in focus: SNAP-25. Int J Biochem Cell Biol 1998; 30: 1069-73.
[21]
Rothman JE. The principle of membrane fusion in the cell (Nobel Lecture). Angew Chem Int Ed 2014; 53(47): 12676-94.
[22]
Torchilin V, Weissig V. Liposomes: A practical approach. US: Oxford University Press 2003.
[23]
Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: An update review. Curr Drug Deliv 2007; 4(4): 297-305.
[24]
Résibois-Grégoire A. Electron microscopic studies of metachromatic leucodystrophy. Acta Neuropathol 1967; 9(3): 244-53.
[25]
Working P, Newman M, Huang S, Mayhew E, Vaage J, Lasic D. Pharmacokinetics, biodistribution and therapeutic efficacy of doxorubicin encapsulated in Stealth® liposomes (Doxil®). J Liposome Res 1994; 4(1): 667-87.
[26]
Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003; 42(6): 463-78.
[27]
Cattel L, Ceruti M, Dosio F. From conventional to stealth liposomes: A new frontier in cancer chemotherapy. Tumori 2003; 89(3): 237-49.
[28]
Immordino ML, Dosio F, Cattel L. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006; 1(3): 297.
[29]
Nag OK, Awasthi V. Surface engineering of liposomes for stealth behavior. Pharmaceutics 2013; 5(4): 542-69.
[30]
Kroon J, Metselaar JM, Storm G, van der Pluijm G. Liposomal nanomedicines in the treatment of prostate cancer. Cancer Treat Rev 2014; 40(4): 578-84.
[31]
Yan F, Li L, Deng Z, et al. Paclitaxel-liposome–microbubble complexes as ultrasound-triggered therapeutic drug delivery carriers. J Control Release 2013; 166(3): 246-55.
[32]
Suk VRE, Misran M. Development and characterization of DOPE PEG2000 coated oleic acid liposomes encapsulating anticancer drugs. J Surfactants Deterg 2017; 20(2): 321-9.
[33]
Luo D, Carter KA, Razi A, et al. Doxorubicin encapsulated in stealth liposomes conferred with light-triggered drug release. Biomaterials 2016; 75: 193-202.
[34]
Zappavigna S, Luce A, Porru M, et al. Stealth liposomes for the delivery of zoledronic acid into tumors enhance the anticancer activity of the drug. Translational Med Rep 2017; 1(2): 6596.
[35]
Zhang XY, Zhang PY. Polymersomes in nanomedicine - A review. Curr Med Chem 2017; 13(2): 124-9.

Rights & Permissions Print Cite
Article Metrics
51
3
1
1
© 2024 Bentham Science Publishers | Privacy Policy